Senseonics (NYSE:SENS) Shares Gap Down – Here’s What Happened

Senseonics Holdings, Inc. (NYSE:SENS)’s share price gapped down before the market opened on Monday . The stock had previously closed at $0.96, but opened at $0.84. Senseonics shares last traded at $0.90, with a volume of 5,892,521 shares traded.

Analysts Set New Price Targets

A number of research firms recently issued reports on SENS. StockNews.com assumed coverage on Senseonics in a report on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Performance

The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. The stock’s 50 day moving average price is $0.58 and its two-hundred day moving average price is $0.44. The firm has a market capitalization of $536.39 million, a PE ratio of -6.95 and a beta of 0.69.

Senseonics (NYSE:SENS) last released its earnings results on Thursday, November 7th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. The firm had revenue of $4.26 million during the quarter, compared to analysts’ expectations of $4.02 million. On average, equities analysts expect that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

Insider Activity at Senseonics

In other news, CEO Timothy T. Goodnow bought 315,000 shares of Senseonics stock in a transaction on Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan bought 124,933 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares of the company’s stock, valued at $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in SENS. FMR LLC grew its stake in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the last quarter. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics in the fourth quarter worth approximately $60,000. GSA Capital Partners LLP acquired a new position in Senseonics in the third quarter worth approximately $117,000. Symmetry Partners LLC acquired a new stake in shares of Senseonics during the 3rd quarter valued at $164,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the last quarter. 12.36% of the stock is currently owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.